| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 36 | 2023 | 75 | 9.400 |
Why?
|
| Imidazoles | 14 | 2019 | 53 | 5.180 |
Why?
|
| Piperazines | 14 | 2019 | 75 | 5.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2022 | 51 | 4.000 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2024 | 57 | 3.460 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 169 | 3.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 18 | 2019 | 27 | 2.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 228 | 2.580 |
Why?
|
| Nuclear Proteins | 13 | 2010 | 80 | 2.490 |
Why?
|
| Cisplatin | 7 | 2022 | 49 | 2.440 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 221 | 2.430 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 56 | 2.010 |
Why?
|
| Apoptosis | 11 | 2019 | 177 | 1.980 |
Why?
|
| Autophagy | 5 | 2021 | 27 | 1.740 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 509 | 1.650 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 14 | 1.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 92 | 1.550 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 369 | 1.490 |
Why?
|
| Tamoxifen | 3 | 2022 | 26 | 1.410 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 9 | 2013 | 19 | 1.410 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2005 | 31 | 1.210 |
Why?
|
| Osteosarcoma | 5 | 2017 | 27 | 1.210 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2020 | 14 | 1.170 |
Why?
|
| Neoplasms | 5 | 2018 | 224 | 1.110 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2010 | 32 | 1.100 |
Why?
|
| Humans | 51 | 2024 | 25692 | 1.060 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 6 | 1.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 4 | 0.920 |
Why?
|
| Cell Nucleus | 7 | 2010 | 73 | 0.870 |
Why?
|
| Transcription Factors | 3 | 2010 | 158 | 0.840 |
Why?
|
| G1 Phase | 6 | 2013 | 13 | 0.830 |
Why?
|
| Cellular Senescence | 3 | 2015 | 17 | 0.830 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2022 | 2 | 0.790 |
Why?
|
| Bone Neoplasms | 4 | 2017 | 104 | 0.780 |
Why?
|
| Active Transport, Cell Nucleus | 4 | 2007 | 11 | 0.770 |
Why?
|
| Mutation | 6 | 2011 | 325 | 0.770 |
Why?
|
| Colonic Neoplasms | 3 | 2014 | 56 | 0.760 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 198 | 0.750 |
Why?
|
| Fatty Acids | 1 | 2021 | 36 | 0.750 |
Why?
|
| Ubiquitins | 6 | 2001 | 9 | 0.720 |
Why?
|
| Animals | 21 | 2022 | 3510 | 0.720 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2012 | 5 | 0.680 |
Why?
|
| Carboxypeptidases | 2 | 2022 | 6 | 0.670 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 19 | 0.670 |
Why?
|
| DNA-Binding Proteins | 5 | 2006 | 249 | 0.660 |
Why?
|
| Glycolysis | 2 | 2018 | 8 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 18 | 0.650 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 41 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.640 |
Why?
|
| Sp1 Transcription Factor | 1 | 2018 | 5 | 0.620 |
Why?
|
| Transfection | 9 | 2020 | 112 | 0.610 |
Why?
|
| Adenosine | 1 | 2018 | 8 | 0.600 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2008 | 5 | 0.590 |
Why?
|
| Tetraploidy | 2 | 2014 | 2 | 0.590 |
Why?
|
| G2 Phase | 3 | 2013 | 4 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 45 | 0.580 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.580 |
Why?
|
| Mice | 11 | 2022 | 1345 | 0.570 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 33 | 0.550 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 6 | 0.530 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 5 | 0.530 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 7 | 0.530 |
Why?
|
| Protein Binding | 8 | 2011 | 116 | 0.520 |
Why?
|
| Signal Transduction | 4 | 2021 | 410 | 0.520 |
Why?
|
| Transcription, Genetic | 3 | 2006 | 100 | 0.520 |
Why?
|
| Cell Lineage | 1 | 2015 | 22 | 0.500 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 72 | 0.500 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2009 | 22 | 0.490 |
Why?
|
| DNA Methylation | 1 | 2016 | 139 | 0.470 |
Why?
|
| Carcinogenesis | 1 | 2014 | 24 | 0.470 |
Why?
|
| Ubiquitin | 2 | 2007 | 23 | 0.470 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 100 | 0.470 |
Why?
|
| Nitric Oxide | 2 | 2014 | 75 | 0.460 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 24 | 0.460 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 12 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 18 | 0.460 |
Why?
|
| Models, Biological | 1 | 2016 | 311 | 0.450 |
Why?
|
| Protein Kinases | 1 | 2014 | 11 | 0.450 |
Why?
|
| DNA Damage | 7 | 2014 | 21 | 0.440 |
Why?
|
| MCF-7 Cells | 3 | 2021 | 13 | 0.430 |
Why?
|
| Staurosporine | 1 | 2013 | 1 | 0.430 |
Why?
|
| Genes, p53 | 3 | 2011 | 16 | 0.420 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2012 | 2 | 0.410 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 11 | 0.410 |
Why?
|
| Paclitaxel | 2 | 2022 | 41 | 0.400 |
Why?
|
| Polyploidy | 2 | 2010 | 2 | 0.400 |
Why?
|
| Ultraviolet Rays | 4 | 2001 | 9 | 0.400 |
Why?
|
| HCT116 Cells | 4 | 2014 | 11 | 0.380 |
Why?
|
| Cell Cycle | 2 | 2010 | 32 | 0.350 |
Why?
|
| Mitosis | 2 | 2008 | 8 | 0.340 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 46 | 0.340 |
Why?
|
| Cytoskeleton | 1 | 2010 | 31 | 0.340 |
Why?
|
| Phosphorylation | 4 | 2016 | 134 | 0.340 |
Why?
|
| Zinc Fingers | 2 | 2000 | 5 | 0.340 |
Why?
|
| RNA Interference | 3 | 2019 | 32 | 0.340 |
Why?
|
| Cell Movement | 1 | 2010 | 70 | 0.340 |
Why?
|
| Cell Line | 7 | 2009 | 268 | 0.340 |
Why?
|
| Puromycin | 1 | 2009 | 1 | 0.330 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2009 | 2 | 0.330 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2009 | 6 | 0.330 |
Why?
|
| Methylation | 2 | 2019 | 7 | 0.330 |
Why?
|
| Cyclin-Dependent Kinases | 3 | 2013 | 3 | 0.330 |
Why?
|
| Enzyme Activation | 3 | 2014 | 108 | 0.320 |
Why?
|
| Histones | 2 | 2019 | 27 | 0.320 |
Why?
|
| Protein Conformation | 2 | 2007 | 69 | 0.320 |
Why?
|
| Genetic Vectors | 1 | 2009 | 50 | 0.320 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 262 | 0.320 |
Why?
|
| DNA Replication | 1 | 2008 | 10 | 0.310 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 103 | 0.310 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 5 | 0.310 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 1 | 0.310 |
Why?
|
| Benzoquinones | 1 | 2008 | 2 | 0.310 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 4 | 0.310 |
Why?
|
| Cell Survival | 4 | 2019 | 110 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 18 | 0.290 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2019 | 5 | 0.280 |
Why?
|
| Oxygen | 3 | 2015 | 74 | 0.270 |
Why?
|
| DNA | 6 | 2008 | 95 | 0.270 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 16 | 0.270 |
Why?
|
| Base Sequence | 7 | 2014 | 90 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 9 | 2001 | 110 | 0.260 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.260 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2005 | 1 | 0.250 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 12 | 0.250 |
Why?
|
| Gamma Rays | 3 | 2012 | 17 | 0.250 |
Why?
|
| Oxidative Stress | 1 | 2005 | 93 | 0.240 |
Why?
|
| RNA, Messenger | 7 | 2012 | 284 | 0.240 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 2 | 0.230 |
Why?
|
| DNA Primers | 4 | 2014 | 46 | 0.230 |
Why?
|
| Interleukin-6 | 1 | 2024 | 74 | 0.230 |
Why?
|
| Protein Structure, Tertiary | 4 | 2006 | 56 | 0.220 |
Why?
|
| Histone Deacetylase 1 | 1 | 2023 | 3 | 0.220 |
Why?
|
| Retinoblastoma Protein | 1 | 2023 | 10 | 0.220 |
Why?
|
| Female | 6 | 2024 | 14273 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 14 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 45 | 0.220 |
Why?
|
| Clone Cells | 2 | 2014 | 9 | 0.210 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 35 | 0.210 |
Why?
|
| Histone Demethylases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Lysine | 1 | 2022 | 13 | 0.210 |
Why?
|
| Cadherins | 1 | 2022 | 28 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 15 | 0.210 |
Why?
|
| CD27 Ligand | 1 | 2022 | 2 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2022 | 48 | 0.210 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 3 | 0.210 |
Why?
|
| Trastuzumab | 1 | 2022 | 21 | 0.200 |
Why?
|
| Nanoparticles | 1 | 2022 | 11 | 0.200 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 184 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 14 | 0.200 |
Why?
|
| Immunoblotting | 4 | 2007 | 50 | 0.200 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 2 | 0.200 |
Why?
|
| Aurora Kinase A | 1 | 2022 | 3 | 0.200 |
Why?
|
| Ribosomal Proteins | 3 | 1990 | 3 | 0.200 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 59 | 0.190 |
Why?
|
| Down-Regulation | 2 | 2001 | 94 | 0.190 |
Why?
|
| CDC2 Protein Kinase | 2 | 2013 | 2 | 0.190 |
Why?
|
| Cyclin B | 2 | 2013 | 3 | 0.190 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2014 | 36 | 0.190 |
Why?
|
| Cyclin A | 2 | 2013 | 3 | 0.190 |
Why?
|
| Alkylating Agents | 1 | 2001 | 1 | 0.190 |
Why?
|
| Mice, Nude | 1 | 2020 | 22 | 0.180 |
Why?
|
| Tumor Protein p73 | 3 | 2006 | 3 | 0.180 |
Why?
|
| Promyelocytic Leukemia Protein | 2 | 2010 | 2 | 0.170 |
Why?
|
| Cyclins | 2 | 1997 | 5 | 0.170 |
Why?
|
| Dexamethasone | 2 | 2012 | 34 | 0.170 |
Why?
|
| Autophagy-Related Proteins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 4 | 0.160 |
Why?
|
| Cytoplasm | 3 | 2007 | 30 | 0.160 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 2 | 0.160 |
Why?
|
| Caspase 3 | 2 | 2022 | 17 | 0.150 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 584 | 0.150 |
Why?
|
| Pyrazines | 1 | 2017 | 9 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2017 | 40 | 0.140 |
Why?
|
| DNA Repair | 2 | 2010 | 5 | 0.130 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 10 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.130 |
Why?
|
| Immunoprecipitation | 2 | 2007 | 21 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 28 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2015 | 107 | 0.130 |
Why?
|
| Multienzyme Complexes | 1 | 1996 | 27 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 6 | 0.130 |
Why?
|
| Macrolides | 1 | 2015 | 5 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Superoxides | 1 | 2015 | 21 | 0.130 |
Why?
|
| Chloroquine | 1 | 2015 | 6 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 23 | 0.130 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 61 | 0.130 |
Why?
|
| Cells, Cultured | 5 | 2007 | 495 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 89 | 0.120 |
Why?
|
| Diploidy | 1 | 2014 | 2 | 0.120 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2014 | 2 | 0.120 |
Why?
|
| Phagosomes | 1 | 2014 | 3 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 8 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 20 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 31 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 66 | 0.110 |
Why?
|
| Plasmids | 2 | 2005 | 37 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2005 | 12 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 8 | 0.110 |
Why?
|
| Leupeptins | 2 | 2006 | 3 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2006 | 6 | 0.100 |
Why?
|
| Caspase 7 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 15 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 14 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2012 | 35 | 0.100 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2005 | 7 | 0.100 |
Why?
|
| Cycloheximide | 2 | 2005 | 9 | 0.100 |
Why?
|
| Mice, Knockout | 4 | 2007 | 284 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 75 | 0.100 |
Why?
|
| Telomere | 1 | 2010 | 6 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 7 | 0.090 |
Why?
|
| Protein Transport | 1 | 2010 | 29 | 0.090 |
Why?
|
| Drosophila | 1 | 1990 | 8 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2001 | 29 | 0.090 |
Why?
|
| Exons | 2 | 2006 | 29 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 14 | 0.090 |
Why?
|
| Stress Fibers | 1 | 2010 | 1 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 5 | 0.090 |
Why?
|
| Focal Adhesions | 1 | 2010 | 4 | 0.090 |
Why?
|
| Actins | 1 | 2010 | 29 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 75 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2010 | 167 | 0.080 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 1 | 0.080 |
Why?
|
| Protein Folding | 1 | 2009 | 20 | 0.080 |
Why?
|
| Time Factors | 2 | 2005 | 1336 | 0.080 |
Why?
|
| Cyclin B1 | 1 | 2008 | 1 | 0.080 |
Why?
|
| HT29 Cells | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cell Division | 1 | 2008 | 79 | 0.080 |
Why?
|
| Binding Sites | 2 | 2005 | 65 | 0.070 |
Why?
|
| Male | 2 | 2020 | 13917 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 22 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 2 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2007 | 55 | 0.070 |
Why?
|
| Luciferases | 1 | 2006 | 26 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2006 | 22 | 0.070 |
Why?
|
| Response Elements | 1 | 2006 | 15 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2006 | 12 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2006 | 68 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2003 | 55 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 93 | 0.060 |
Why?
|
| Radiation, Ionizing | 1 | 2005 | 1 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
|
| Etoposide | 1 | 2005 | 25 | 0.060 |
Why?
|
| Interferon-gamma | 3 | 2001 | 75 | 0.060 |
Why?
|
| Cyclin E | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Serine | 1 | 2005 | 9 | 0.060 |
Why?
|
| Densitometry | 1 | 2005 | 9 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 17 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2005 | 39 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2005 | 43 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2004 | 49 | 0.060 |
Why?
|
| Interleukin-12 | 2 | 2001 | 33 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 11 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 24 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 41 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 29 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2001 | 7 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2001 | 7 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 9 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2001 | 17 | 0.050 |
Why?
|
| Epitopes | 1 | 2001 | 44 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 71 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2001 | 10 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2001 | 24 | 0.050 |
Why?
|
| Methyl Methanesulfonate | 1 | 2001 | 1 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2001 | 5 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 40 | 0.050 |
Why?
|
| Macrophages | 1 | 2001 | 97 | 0.050 |
Why?
|
| Mitomycin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Salmon | 1 | 2000 | 1 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2001 | 43 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1990 | 2 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 103 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 31 | 0.040 |
Why?
|
| Ligases | 1 | 1999 | 10 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1999 | 5 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2001 | 178 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 1999 | 36 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 1999 | 11 | 0.040 |
Why?
|
| Point Mutation | 1 | 1999 | 25 | 0.040 |
Why?
|
| S Phase | 1 | 1998 | 10 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1996 | 14 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 118 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 169 | 0.030 |
Why?
|
| Introns | 2 | 2001 | 16 | 0.030 |
Why?
|
| Gene Expression | 1 | 1996 | 182 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 183 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1990 | 7 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 1990 | 137 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 1990 | 31 | 0.020 |
Why?
|
| Killer Cells, Natural | 2 | 2001 | 46 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2001 | 405 | 0.020 |
Why?
|
| Multigene Family | 1 | 1989 | 8 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1989 | 9 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 1989 | 13 | 0.020 |
Why?
|
| Blotting, Western | 2 | 1998 | 140 | 0.020 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2001 | 1 | 0.010 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2001 | 3 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 2001 | 6 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2001 | 6 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2001 | 22 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2001 | 1 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 4 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 11 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 19 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2001 | 25 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 98 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 7 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 30 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 78 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 118 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 150 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 157 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 127 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 217 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2001 | 52 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1999 | 11 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1999 | 29 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 52 | 0.010 |
Why?
|
| Transposases | 1 | 1999 | 1 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1999 | 3 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 32 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1998 | 4 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 111 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 132 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1998 | 154 | 0.010 |
Why?
|
| Autoradiography | 1 | 1995 | 3 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 6 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1990 | 3 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1990 | 9 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 24 | 0.010 |
Why?
|